Advertisement Pharmaceutical Business review -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 17, 2022

US FDA approves Pfizer’s Cibinqo for atopic dermatitis treatment

The US Food and Drug Administration (FDA) has approved Pfizer’s Cibinqo (abrocitinib) to treat moderate-to-severe atopic dermatitis (AD) in adult patients.

The 100mg and 200mg doses of Cibinqo are recommended by FDA to treat AD adult patients. Credit: Hal Gatewood on Unsplash.